Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.70% | 6.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.70% | 6.97% | |||
| Cost of Revenue | 29.76% | 7.97% | |||
| Gross Profit | 0.15% | 6.92% | |||
| SG&A Expenses | 4.49% | -6.72% | |||
| Depreciation & Amortization | 0.00% | 0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.45% | -3.90% | |||
| Operating Income | -28.99% | 18.75% | |||
| Income Before Tax | -33.86% | 18.62% | |||
| Income Tax Expenses | 1,877.83% | 24.43% | |||
| Earnings from Continuing Operations | -525.11% | 16.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -525.11% | 16.98% | |||
| EBIT | -28.99% | 18.75% | |||
| EBITDA | -31.02% | 19.88% | |||
| EPS Basic | -525.07% | 17.13% | |||
| Normalized Basic EPS | -41.06% | 18.75% | |||
| EPS Diluted | -525.07% | 17.13% | |||
| Normalized Diluted EPS | -41.06% | 18.75% | |||
| Average Basic Shares Outstanding | 0.01% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||